Stock PMED PEPTONIC MEDICAL AB
Add to a list
To use this feature you must be a member
Log inSign up

PEPTONIC medical AB Stock

Equities

PMED

SE0005962206

Biotechnology & Medical Research

End-of-day quote NORDIC GROWTH MARKET
Other stock markets
 06:00:00 2024-01-30 pm EST 		5-day change 1st Jan Change
0.06 SEK -.--% Intraday chart for PEPTONIC medical AB -.--% +3.45%
Apr. 17 Peptonic Medical Plans SEK61 Million Shares, Warrants Issue MT
Apr. 15 Peptonic Medical Secures US Patent for Vaginal Yeast Infections Treatment MT

Financials

Sales 2020 21.28 232.83 Sales 2021 31.64 346.17 Capitalization 120M 1.31B
Net income 2020 -31M -339M Net income 2021 -73M -799M EV / Sales 2020 11,379,940 x
Net cash position 2020 39.31M 430M Net cash position 2021 10.15M 111M EV / Sales 2021 3,464,329 x
P/E ratio 2020
-9.05 x
P/E ratio 2021
-1.63 x
Employees 32
Yield 2020 *
-
Yield 2021
-
Free-Float 7.47%
More Fundamentals * Assessed data

Chart PEPTONIC medical AB

Dynamic Chart

Latest news about PEPTONIC medical AB

Peptonic Medical Plans SEK61 Million Shares, Warrants Issue MT
Peptonic Medical Secures US Patent for Vaginal Yeast Infections Treatment MT
Sweden’s Peptonic Medical Enters Benelux Distribution Deal for Women's Self-care Products MT
Peptonic Medical AB Strengthens Its Position in Europe Through an Exclusive Distribution Agreement for Vagivital and Vernivia in the Benelux Region CI
Peptonic Medical CFO to Depart in Mid-June MT
PEPTONIC medical AB Announces Resignation of Albert Lindgren as CFO CI
Farmasiet Extends Partnership with Peptonic Medical, Bringing VagVital's Product Portfolio to Norway CI
Peptonic Medical AB Announces Patented Apoteket Offering in 293 Apoteket Stores CI
PEPTONIC medical AB completed the acquisition of Pharmiva AB (OM : PHARM). CI
Peptonic Medical Gains on Deal with Al Fotune for VagiVital VS Pro Distribution in UAE MT
Peptonic Medical AB Signs Distribution Agreement with Al Fotune for United Arab Emirate CI
Peptonic Medical AB's Self-Test for Bacterial Vivinosis to Be Sold in over 220 Apoteket Stores CI
PEPTONIC medical AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Peptonic Medical Lands First Vaginal Self-test Order for Central American Market MT
Peptonic Medical AB Receives First Order in Central America from Windsor Pharmaceuticals CI
More news

Analyst Recommendations on PEPTONIC medical AB

Sweden’s Peptonic Medical Enters Benelux Distribution Deal for Women's Self-care Products MT
More recommendations

Press releases PEPTONIC medical AB

The last day of trading with the warrants of series TO4 in PEPTONIC medical AB is today, April 26, 2024 AQ
The board of Peptonic resolves, subject to approval of the general meeting, on a rights issue of units of approximately SEK 61.4 million AQ
The subscription price for the warrants of series TO4 in PEPTONIC medical AB has been determined to SEK 0.028 and the exercise period starts April 17, 2024 AQ
Peptonic Medical AB granted patent in the USA for treatment and prevention of yeast infections among women AQ
Peptonic Medical AB strengthens its position in Europe through an exclusive distribution agreement for VagiVital and Vernivia in the Benelux region AQ
More press releases

Quotes and Performance

6 months-23.08%
Current year+3.45%
More quotes

Highs and lows

Current year
0.05
Extreme 0.054
0.07
1 year
0.05
Extreme 0.05
0.13
3 years
0.05
Extreme 0.05
1.46
5 years
0.05
Extreme 0.05
4.10
10 years
0.05
Extreme 0.05
19.50
More quotes

Managers and Directors - PEPTONIC medical AB

Managers TitleAgeSince
Erik Sundquist CEO
 Chief Executive Officer 54 21-04-13
Albert Lindgren DFI
 Director of Finance/CFO - 23-10-20
Hadar Kessary CTO
 Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Tarek Shoeb BRD
 Director/Board Member 55 23-05-23
Karl Blom BRD
 Director/Board Member 55 -
Anders Norling BRD
 Director/Board Member 58 22-05-23
More insiders

Company Profile

Peptonic Medical AB is a Sweden-based company active in the field of biotechnology. The Company develops estrogen-free pharmaceuticals for treatment of vaginal atrophy. The Company's main drug candidate is Vagitocin, an oxytocin-based pharmaceutical preparation for the treatment of vaginal atrophy and other menopause-related symptoms. The patented treatment is based on local, vaginal application of oxytocin to rejuvenate the vaginal mucosa. Vagitocin is to enter phase III clinical trials in Europe and the United States.
Sector
Biotechnology & Medical Research
Calendar
2024-05-06 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

1st Jan change Capi.
PEPTONIC MEDICAL AB Stock PEPTONIC medical AB
+3.45% 8.4M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. PMED Stock